Left-ventricular-assist-device (LVAD) implantation in patients with antiphospholipid-syndrome (APS) is considered a high-risk procedure and its indication still represents an open challenge. Herein, we report a 63-year-old man with APS and end-stage heart failure, for whom a HeartMate3-LVAD and a continuous rheologic profile monitoring with a multiparametric assessment resulted the optimal therapeutic strategy.
LimWCrowtherMAEikelboomJW, et al. Management of antiphospholipid antibody syndrome: a systematic review. JAMA2006; 295: 1050–1057.
2.
GandhiMJPierceRAZhangL, et al. Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant. J Cardiothorac Surg2007; 2: 32.
3.
RogersJGPaganiFDTatoolesAJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med2017; 376: 451–460.
4.
SlaughterMSRogersJGMilanoCA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med2009; 361: 2241–2251.
5.
TarziaVBottioTBurattoE, et al. The hazard of comparing apples and oranges: the proper indication for the use of recombinant activated clotting factor VII in cardiac surgery. J Thorac Cardiovasc Surg2011; 142: 1588–1589.
6.
AlvarezPCordero-ReyesAMUribeC, et al. Acquired and hereditary hypercoagulable states in patients with continuous flow left ventricular assist devices: prevalence and thrombotic complications. J Card Fail2016; 22: 501–511.
7.
WadiaYThiagarajanPDelgadoR, et al. Antiphospholipid syndrome with anti-prothrombin autoantibodies in a patient with an axial flow left ventricular assist device. J Heart Lung Transplant2005; 24: 1133–1136.
8.
MeyerALKuehnCGrasC, et al. Implantation of a left ventricular assist device in a patient with primary antiphospholipid syndrome. Ann Thorac Surg2008; 86: 639–640.
9.
ReadeCCMorrisRJAckerMA, et al. Acute myocardial infarction requiring mechanical bridge to transplantation in a patient with undiagnosed anti-phospholipid antibody syndrome. J Heart Lung Transplant2008; 27: 682–684.
10.
KrabatschTNetukaISchmittoJD, et al. Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure –1 year results from the CE mark trial. J Cardiothorac Surg2017; 12: 23.
11.
UrielNColomboPCClevelandJC, et al. Hemocompatibility-related outcomes in the MOMENTUM 3 trial at 6 months. A randomized controlled study of a fully magnetically levitated pump in advanced heart failure. Circulation2017; 135: 2003–2012.
12.
NetukaIIvákPTučanováZ, et al. Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM-1 study. J Heart Lung Transplant2018; 37: 579–586.
13.
SaeedOColomboPCMehraMR, et al. Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: an analysis from the MOMENTUM 3 study. J Heart Lung Transplant2020; 39: 518–525.
